halo thanks

Article

Your one click will help provide emergency medical care to millions of people caught in crises in nearly 60 countries around the world.

Thank you for joining the movement.

Your one click will help provide emergency medical care to millions of people caught in crises in nearly 60 countries around the world.

Now, help spread the word!

Just one more click helps us spread the movement far and wide. Be sure to share this link with your friends and colleagues in the healthcare profession.

 

Thank you for spreading the word!

 

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content
Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.

Sirexatamab Combo Significantly Improves PFS in MSS CRC Subgroups

Russ Conroy
June 28th 2025
Article

Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

Radhika Appaya;Erika P. Hamilton, MD;Thomas Decker;Hope S. Rugo, MD;Maria Fernandez Abad;Kevin Kalinsky, MD, MS;Qiang Liu;Mariya Rozenblit, MD;Barbara Radecka;Seock-Ah Im;Frances Visco;Alejandro Perez;Yogesh Chattar;Murat Akdere;Vaidyanathan Ganapathy;Sorcha Waters;Joyce O’Shaughnessy, MD
June 27th 2025
Article

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.

Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.

Immunotherapy Rechallenge Exhibits Feasibility in Pretreated ES-SCLC

Roman Fabbricatore
June 27th 2025
Article

Larger multi-center trials could further elucidate the long-term outcomes of anlotinib plus immune checkpoint inhibition in this patient group.

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.

Certepetide Displays Positive Efficacy Trend in Metastatic PDAC

Roman Fabbricatore
June 27th 2025
Article

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.